Datroway
datopotamab deruxtecan
APPROVED
Drug Profile
ModalityADC
RouteIV
Therapy AreaOncology
Launch2024-01-17
US LOE2038-01-01
Peak Sales Est$5000M
Formulations[{"id":"datroway-iv-1","route":"IV","setting":"HCP_ONLY","duration":"60-minute infusion","frequency"
Mechanism: TROP2-directed (DXd payload)
Expert: Anti-TROP2 antibody conjugated to DXd payload via cleavable linker. TROP2 overexpression in breast, lung, and other epithelial cancers provides broad tumor targeting with favorable therapeutic index.
Everyday: An antibody-drug conjugate that targets TROP2 protein found on many solid tumors, delivering chemotherapy directly to cancer cells.
Targets: ["TROP2"]
Revenue History
| Period | Revenue ($M) |
|---|
| 2024 | $142M |
| Q1 2025 | $68M |
| Q2 2025 | $95M |
Programs (3)
| Indication | Stage | Key Study | Regional Status |
|---|
| NSCLC (EGFRm/Dato) | PHASE3 | TROPION-Lung01 | [] |
| HR+/HER2- BC | APPROVED | TROPION-Breast01 | [{"stage":"APPROVED","region":"US","approval_date":"2024-01-17"}] |
| NSCLC | FILED | TROPION-Lung01 | [] |
Upcoming Catalysts (5)
Datroway - TROP2 Biomarker-Directed - Ph3 - Start (TROPION-Lung17)
Jan 2026
Datroway - 1L mTNBC (PD-L1 neg) - FDA Approval
Q2 2026
Datroway + Imfinzi - 1L NSCLC - Ph3 - Topline (AVANZAR)
H2 2026
Datroway + Keytruda - 1L NSCLC PD-L1 High - Ph3 - Topline (TROPION-Lung08)
H2 2026
Datroway + Keytruda - 1L NSCLC PD-L1 Low - Ph3 - Topline (TROPION-Lung07)
H2 FY2026
Notes
TROP2-directed ADC with DXd payload. Approved Jan 2025 for HR+/HER2- mBC. Phase 3 ongoing in NSCLC (TROPION-Lung01). 50/50 partnership with AstraZeneca.
Data from Supabase · Updated 2026-03-24